David A. Siegel Chemomab Therapeutics Ltd. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Chemomab Therapeutics Ltd. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 37,800 shares of CMMB stock, worth $34,398. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,800
Previous 35,400
6.78%
Holding current value
$34,398
Previous $18,000
61.11%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CMMB
# of Institutions
16Shares Held
2.66MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA2.24MShares$2.04 Million0.04% of portfolio
-
Ikarian Capital, LLC Dallas, TX213KShares$194,1860.02% of portfolio
-
Two Sigma Investments, LP New York, NY40KShares$36,3940.0% of portfolio
-
Kestra Private Wealth Services, LLC31.2KShares$28,4290.0% of portfolio
-
Boothbay Fund Management, LLC New York, NY26.5KShares$24,1410.0% of portfolio
About Chemomab Therapeutics Ltd.
- Ticker CMMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,431,700
- Market Cap $10.4M
- Description
- Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...